Benitec Biopharma Inc. (BNTC)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade
Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 83.9% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know
The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Benitec Biopharma Inc. (BNTC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Benitec Biopharma Inc. ever had a stock split?
Benitec Biopharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jerel A. Banks CEO | NASDAQ (CM) Exchange | 08205P100 CUSIP |
| US Country | 16 Employees | - Last Dividend | 26 Jul 2023 Last Split | 18 Aug 2015 IPO Date |
Overview
Benitec Biopharma Inc. is a pioneering clinical-stage biotechnology company fervently engaged in the advancement of innovative genetic medicines. With a keen focus on tackling chronic and life-threatening human conditions, Benitec's scientific endeavors are powered by DNA-directed RNA interference (RNAi) technology. This groundbreaking approach allows for the precise silencing of specific genes responsible for disease, heralding a new era in medical therapy. Since its incorporation in 1995, the company has been at the forefront of genetic research and therapy development, establishing its headquarters in Hayward, California.
Products and Services
BB-301
At the core of Benitec Biopharma's innovative product pipeline stands BB-301, an adeno-associated virus (AAV) based gene therapy agent. This leading-edge treatment is designed specifically for patients suffering from oculopharyngeal muscular dystrophy (OPMD), a rare and debilitating genetic condition. OPMD often leads to progressive muscle weakness, affecting vital functions such as eye movement and swallowing. By harnessing the power of gene therapy, BB-301 aims to correct the genetic abnormalities at the root of OPMD, offering hope for a significant improvement in the quality of life for patients afflicted by this challenging condition.
